French vascular physicians' practices in indicating antiplatelet and anticoagulation therapy in venous thromboembolism.
CONCLUSIONS: French vascular physicians adopted different strategies according to estimated risk/benefit ratio. Prospective randomized controlled trials should compare these strategies in order to make recommendations. PMID: 30945997 [PubMed - as supplied by publisher]
CONCLUSIONS: The study evaluated the safety of withdrawing the P2Y 12 inhibitor from triple antithrombotic prescription 1 month after coronary stenting. However, enrollment was prematurely terminated because it was slow. Therefore, statistical power was not sufficient to assess the differences in the primary endpoint. PMID: 32091400 [PubMed - as supplied by publisher]
In conclusion, romiplostim dosing, effectiveness and safety in these unselected ITP patients seemed comparable with observations in clinical trials and similarly designed observational studies.
Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic medication for acute ischemic stroke. However, multiple recent studies comparing tenecteplase and alteplase suggest that tenecteplase is at least as efficacious as alteplase with regards to neurologic improvement. When given at 0.25 milligrams per kilogram (mg/kg), tenecteplase may have less bleeding complications than alteplase as well. This narrative review evaluates the literature and addresses the practical issues with regards to the use of tenecteplase versus alteplase for acute ischemic stroke, and it recommends that physicians ...
Authors: Herold A Abstract Hemorrhoidal disease is one of the most common illnesses in industrialized nations. Up to 70% of adults suffer from the disease once in their lifetime. This underlines the necessity and importance of knowing about the differential diagnosis of hemorrhoids. One can differentiate between differential diagnoses of symptoms (bleeding, pain, itching, tumor) and differential diagnoses of the phenotype findings (anal prolapse, mucosal prolapse and rectal prolapse, skin tags, hypertrophied anal papillae, condylomata acuminata, anal fissure, perianal venous thrombosis, anal cancer). PMID: 3207...
AbstractPatients with polycythemia vera (PV) or essential thrombocythemia (ET) presenting with splanchnic vein thrombosis (SVT) might have a specific clinico-biological profile. To investigate this hypothesis, 3705 PV/ET patients from three national registers, 118 of them presenting with SVT, were reviewed. After correction for age and sex, PV/ET patients with SVT showed an increased risk of death (HR 2.47, 95% CI 1.5 –4.01,p
The Joint Outcome Study demonstrated that prophylactic therapy reduced joint bleeding and improved joint status. However, magnetic resonance imaging (MRI) revealed that the joints of patients who had no clinically evident joint bleeding (CEJB) displayed some abnormalities indicative of hemophilic arthropathy . One explanation might be the presence of subclinical joint bleeding that passed unrecognized by patients. However, although many reports have implied their existence [1,2], such bleeds have remained unproven.
The objective of our study was to describe DOAC management in patients who were and were not managed by an AMS. We conducted a retrospective cohort study among patients with atrial fibrillation at the University of Utah Health (UUH) who received DOAC therapy between January 2013 and June 2016. Patients in the AMS group were managed by a pharmacist-led AMS whereas those in the non-AMS group were managed by other providers. The number and type of provider encounters and interventions related to DOAC therapy and a composite endpoint of thromboembolism, bleeding, and all-cause mortality were recorded. Overall, 90 and 370 patie...
In conclusion, the effects of 1-month DAPT for the primary and major secondary endpoints were consistent in HBR and non-HBR patients without any significant interactions. The benefit of 1-month DAPT in reducing major bleeding was numerically greater in HBR patients.Clinical trial registration Short and optimal duration of dual antiplatelet therapy after everolimus-eluting cobalt –chromium stent-2 [STOPDAPT-2]; NCT02619760.
Abnormal uterine bleeding (AUB) affects up to two thirds of women on anticoagulation (AC) therapy. In women on AC for venous thromboembolism (VTE), AUB is linked to recurrent VTE, likely due to interrupted therapy. Treatment options for anticoagulant-associated AUB (AA-AUB) are limited, as estrogen-containing treatments increase thrombotic risk and endometrial ablation or hysterectomy lead to infertility. While uterine artery embolization (UAE) is a well-established treatment for symptomatic fibroids, its role in acute AA-AUB is limited to case reports.
This article explores the prevention and management of common surgical complications which a junior surgical trainee is likely to face.